Trailing rivals, AstraZeneca offers a hit and a miss on key cardio study for SGLT2 diabetes drug Farxiga
AstraZeneca had some good news for its investors early Monday morning, reporting that their Phase III cardio study offered some compelling proof of their SGLT2 diabetes drug’s ability to reduce the risk of hospitalization for heart failure and CV death. But it was a mixed picture, with Farxiga falling short on a primary endpoint for major reduction in major cardiac events compared to a placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.